Skip to main content

Publications by Torbjörn Gräslund

Refereegranskade

Artiklar

[3]
S. M. Deyev et al., "Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1," International Journal of Biological Macromolecules, vol. 145, pp. 216-225, 2020.
[8]
M. Altai et al., "Affibody-derived drug conjugates : Potent cytotoxic molecules for treatment of HER2 over-expressing tumors," Journal of Controlled Release, vol. 288, pp. 84-95, 2018.
[10]
S. Ståhl et al., "Affibody Molecules in Biotechnological and Medical Applications," Trends in Biotechnology, vol. 35, no. 8, pp. 691-712, 2017.
[11]
T. Gräslund, "Affibody molecules : therapy and in vivo diagnostic applications," New Biotechnology, vol. 33, pp. S48-S48, 2016.
[13]
M. Altai et al., "Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin," International Journal of Oncology, vol. 49, no. 3, pp. 1185-1194, 2016.
[17]
J. Seijsing et al., "An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 48, pp. 17110-17115, 2014.
[21]
L. M. Orre et al., "S100A4 interacts with p53 in the nucleus and promotes p53 degradation," Oncogene, vol. 32, no. 49, pp. 5531-5540, 2013.
[24]
K. Larsson et al., "Novel antigen design for the generation of antibodies to G-protein-coupled receptors," JIM - Journal of Immunological Methods, vol. 370, no. 1-2, pp. 14-23, 2011.
[28]
J. Li et al., "Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor," Biotechnology and applied biochemistry, vol. 55, pp. 99-109, 2010.
[30]
E. Lundberg, H. Brismar and T. Gräslund, "Selection and characterization of Affibody (R) ligands to the transcription factor c-Jun," Biotechnology and applied biochemistry, vol. 52, pp. 17-27, 2009.
[31]
E. Vernet et al., "Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule," Journal of immunological methods, vol. 338, pp. 1-6, 2008.
[32]
E. Lundberg et al., "A novel method for reproducible fluorescent labeling of small amounts of antibodies on solid phase," JIM - Journal of Immunological Methods, vol. 322, no. 1-2, pp. 40-49, 2007.
[33]
R. M. Gordley et al., "Evolution of programmable zinc finger-recombinases with activity in human cells," Journal of Molecular Biology, vol. 367, no. 3, pp. 802-813, 2007.
[34]
[36]
T. Gräslund et al., "Exploring strategies for the design of artificial transcription factors," Journal of Biological Chemistry, vol. 280, no. 5, pp. 3707-3714, 2005.
[37]
M. Hedhammar, T. Gräslund and S. Hober, "Protein engineering strategies for selective protein purification," Chemical Engineering & Technology, vol. 28, no. 11, pp. 1315-1325, 2005.
[38]
M. Linhult et al., "Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach," Proteins : Structure, Function, and Bioinformatics, vol. 55, no. 2, pp. 407-416, 2004.
[39]
M. Hedhammar et al., "Negatively charged purification tags for selective anion-exchange recovery," Protein Engineering Design & Selection, vol. 17, no. 11, pp. 779-786, 2004.
[43]
T. Gräslund et al., "Strategy for highly selective ion-exchange capture using a charge-polarizing fusion partner," Journal of Chromatography A, vol. 942, no. 1-2, pp. 157-66, 2002.
[44]
T. Gräslund et al., "Strategy for highly selective ion-exchange capture using a charge-polarizing fusion partner," Journal of Chromatography A, vol. 942, no. 1-2, pp. 157-166, 2002.
[46]
T. Gräslund et al., "Charge engineering of a protein domain to allow efficient ion-exchange recovery," Protein Engineering, vol. 13, no. 10, pp. 703-709, 2000.
[48]
T. Gräslund et al., "Production of a Thermostable DNA Polymerase by Site-Specific Cleavage of a Heat-Eluted Affinity Fusion Protein," Protein Expression and Purification, vol. 9, pp. 125-132, 1997.

Icke refereegranskade

Artiklar

[49]
T. Xu et al., "Evaluation of Molecular Design of HER2-targeting Affibody-drug Conjugates for Drug Delivery to Ovarian Cancer," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, pp. S10-S10, 2020.
[50]
M. Altai et al., "Evaluation Of Several Newly Designed Affibody-based Drug Conjugates Using Radionuclide-based Techniques : A Powerful Tool For Drug Development," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, pp. S715-S716, 2019.
[51]
A. Vorobyeva et al., "Imaging of EpCAM expression in pancreatic cancer using radiolabelled DARPin Ec1," European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. SUPPL 1, pp. S749-S750, 2019.
[52]
M. Altai et al., "Improving of molecular design of a novel Affibody-fused HER2-recognising anticancer toxin using radionuclide-based techniques," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, pp. S178-S178, 2016.
[53]
V. Tolmachev et al., "HEHEHE : a new chelator for [Tc-99m(CO)(3)](+)-labeling assembling His(6)-tag in protein purification," Nuclear Medicine and Biology, vol. 37, no. 6, pp. 698-698, 2010.
[54]
L. M. Orre et al., "FUNCTIONAL STUDIES OF S100A6 USING PROTEOMICS," Anticancer Research, vol. 28, no. 5C, pp. 3430-3431, 2008.

Övriga

Patent

Patent

[66]
R. Lewensohn et al., "S100a6 and/or s100a4 inhibitors for treating cancer," WO 2009109862A3 , 2008.
[67]
T. Gräslund et al., "IGF-1R binding polypeptides and their use," us 8426557B2 (2013-04-23), 2007.
Senaste synkning med DiVA:
2021-07-25 01:49:51